COVID-19: Clouds Over the Antimicrobial Resistance Landscape

被引:17
|
作者
Rodriguez-Alvarez, Mauricio [1 ]
Lopez-Vidal, Yolanda [1 ]
Luis Soto-Hernandez, Jose [2 ]
Guadalupe Miranda-Novales, Maria [3 ]
Flores-Moreno, Karen [4 ]
Ponce de Leon-Rosales, Samuel [5 ]
机构
[1] Univ Nacl Autonoma Mexico, Dept Microbiol & Parasitol, Fac Med, Ave Univ 3000, Mexico City 04510, DF, Mexico
[2] Inst Nacl Neurol & Neurocirugia Manuel Velasco Su, Dept Infectol, Mexico City, DF, Mexico
[3] Ctr Med Nacl Siglo XXI, Unidad Invest Anal & Sintesis Evidencia, Inst Mexicano Seguro Social, Mexico City, DF, Mexico
[4] Univ Nacl Autonoma Mexico, Lab Microbioma, Fac Med, Mexico City, DF, Mexico
[5] Univ Nacl Autonoma Mexico, Programa Univ Invest Salud, Mexico City, DF, Mexico
关键词
Anti-bacterial agents; Antimicrobial stewardship; Coronavirus pandemic; Drug resistance; Microbial;
D O I
10.1016/j.arcmed.2020.10.010
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In recent years, the increase in antimicrobial resistance (AMR) has been recognized as a real threat to human and animal health. It is a problem that has been given the highest priority, uniting nations in the fight against its causes and effects. Among the actions that have been implemented are: clinical and microbiological surveillance, promotion of rational and controlled use of antibiotics, AMR stewardship programs in hospitals, development of tools for rapid diagnosis of infectious diseases to establish prompt and adequate treatment, and radically improving vaccination strategies. The current COVID-19 pandemic has placed disproportionate demands on the healthcare infrastructure and economy worldwide, which will negatively impact on the availability of materials as well as the technical capacity for diagnosis, patient care, and treatment of both COVID-19 and non-COVID-19 patients. Disruptions to production and distribution chains will hamper the availability and usage of antibiotics, also interrupting several of the activities that have been implemented thus far to combat AMR, including detailed laboratory monitoring and reinforced vaccination programs. Here, we discuss the main aspects that should be considered with regard to AMR, that may be affected by the pandemic and propose some actions to counter them. (c) 2020 IMSS. Published by Elsevier Inc.
引用
收藏
页码:123 / 126
页数:4
相关论文
共 50 条
  • [41] Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance?
    Monnet, Dominique L.
    Harbarth, Stephan
    EUROSURVEILLANCE, 2020, 25 (45) : 1 - 6
  • [42] Antimicrobial resistance and COVID-19 syndemic: Impact on public health
    Vidyarthi, Ashima Jain
    Das, Arghya
    Chaudhry, Rama
    DRUG DISCOVERIES AND THERAPEUTICS, 2021, 15 (03): : 124 - 129
  • [43] Antimicrobial Resistance, the COVID-19 Pandemic, and Lessons for the Orthopaedic Community
    Metsemakers, Willem-Jan
    Zalavras, Charalampos
    Schwarz, Edward M.
    Chen, Antonia F.
    Trampuz, Andrej
    Moriarty, T. Fintan
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2021, 103 (01): : 4 - 9
  • [44] COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance
    Bou-Antoun, Sabine
    Rokadiya, Sakib
    Ashiru-Oredope, Diane
    Demirjian, Alicia
    Sherwood, Emma
    Ellaby, Nicholas
    Gerver, Sarah
    Grossi, Carlota
    Harman, Katie
    Hartman, Hassan
    Lochen, Alessandra
    Ragonnet-Cronin, Manon
    Squire, Hanna
    Sutton, J. Mark
    Thelwall, Simon
    Tree, Julia
    Bahar, Mohammad W.
    Stuart, David, I
    Brown, Colin S.
    Chand, Meera
    Hopkins, Susan
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 : 37 - 42
  • [45] Exacerbation of antimicrobial resistance: another casualty of the COVID-19 pandemic?
    Razzaque, Mohammed S.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2021, 19 (08) : 967 - 971
  • [46] Antimicrobial resistance in the times of COVID-19 in a roman teaching hospital
    Fontana, Carla
    Favaro, Marco
    Minelli, Silvia
    Bossa, Maria Cristina
    Altieri, Anna
    Celeste, Mariagrazia
    Pennacchiotti, Carla
    Sarmati, Loredana
    Andreoni, Massimo
    Cucchi, Carmela
    Magrini, Andrea
    ALL LIFE, 2022, 15 (01) : 452 - 457
  • [47] COVID-19 drug practices risk antimicrobial resistance evolution
    Afshinnekoo, Ebrahim
    Bhattacharya, Chandrima
    Burguete-Garcia, Ana
    Castro-Nallar, Eduardo
    Deng, Youping
    Desnues, Christelle
    Dias-Neto, Emmanuel
    Elhaik, Eran
    Iraola, Gregorio
    Jang, Soojin
    Labaj, Pawel P.
    Mason, Christopher E.
    Nagarajan, Niranjan
    Poulsen, Michael
    Prithiviraj, Bharath
    Siam, Rania
    Shi, Tieliu
    Suzuki, Haruo
    Werner, Johannes
    Mercedes Zambrano, Maria
    Bhattacharyya, Malay
    LANCET MICROBE, 2021, 2 (04): : E135 - E136
  • [48] The Covid-19 threat landscape
    Sood A.K.
    Talluri S.
    Nagal A.
    SL R.R.
    D B.R.
    Chaturvedi R.
    Computer Fraud and Security, 2021, 2021 (09): : 10 - 15
  • [49] COVID-19: The therapeutic landscape
    Paules, Catharine, I
    Fauci, Anthony S.
    MED, 2021, 2 (05): : 493 - +
  • [50] The COVID-19 Vaccine Landscape
    Koch, Till
    Fathi, Anahita
    Addo, Marylyn M.
    CORONAVIRUS DISEASE - COVID-19, 2021, 1318 : 549 - 573